Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
icad inc is a medical devices business based in the US. icad shares (ICAD) are listed on the NASDAQ and all prices are listed in US Dollars. icad employs 136 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.95 |
|---|---|
| 52-week range | $2.91 - $17.30 |
| 50-day moving average | $3.82 |
| 200-day moving average | $6.22 |
| Wall St. target price | $13.83 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.52 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.95 from 2022-07-01
| 1 week (2022-06-27) | -7.28% |
|---|---|
| 1 month (2022-06-03) | -0.25% |
| 3 months (2022-04-04) | -6.40% |
| 6 months (2022-01-04) | -32.82% |
| 1 year (2021-07-02) | -77.13% |
|---|---|
| 2 years (2020-07-02) | -59.78% |
| 3 years (2019-07-03) | 6.18 |
| 5 years (2017-07-03) | 4.03 |
| Revenue TTM | $32.5 million |
|---|---|
| Gross profit TTM | $24.6 million |
| Return on assets TTM | -11.84% |
| Return on equity TTM | -27.08% |
| Profit margin | -40.43% |
| Book value | $1.74 |
| Market capitalisation | $99.5 million |
TTM: trailing 12 months
We're not expecting icad to pay a dividend over the next 12 months.
icad's shares were split on a 1:5 basis on 15 August 2012. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your icad shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for icad shares which in turn could have impacted icad's share price.
Over the last 12 months, icad's shares have ranged in value from as little as $2.91 up to $17.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while icad's is 1.2718. This would suggest that icad's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.